Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine Plus High-Dose Ascorbate in Sarcomas
NCT04634227Phase 1Active, not recruiting
- Sponsor
- University of Iowa
- Start
- Nov 2020
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ascorbic acid in soft tissue sarcoma (STS) and bone sarcoma, sponsored by University of Iowa. Primary endpoint: Progression-Free Survival at 12 weeks. Started Nov 2020; status: active, not recruiting.
02
Drugs
ascorbic acid
03
Conditions
soft tissue sarcoma (STS)bone sarcoma
Beyond the preview
Go deeper on NCT04634227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04634227.